Osimertinib ± Savolitinib in MET-EGFR NSCLC Trial

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...
ascopubs.org

Impact of epidermal growth factor receptor (EGFR) pathway alterations on the outcome of non-small cell lung cancer (NSCLC) patients (pts) treated with first-line chemotherapy (CHT)

3p and 10q deletions detected by fluorescence in situ hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC) ...
BioWorld

mRNA-based cancer vaccine targeting mutated EGFR shows antitumor efficacy

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.
News Medical

Study unlocks the healing power of oral keratinocytes

Moreover, the researchers observed reciprocal interaction between Src and EGFR in oral keratinocytes. The activation of Src, a non-receptor tyrosine kinase, appeared to transduce signals from various ...
The Manila Times

Subcutaneous RYBREVANT® (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell ...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...